Mazdutide Shows Strong Efficacy for Type 2 Diabetes and Weight Loss in Chinese Adults

Globally, type 2 diabetes (T2D) is a chronic metabolic disorder characterized by high blood sugar, affecting millions and leading to severe complications like cardiovascular disease and kidney failure. Current treatments often struggle to achieve optimal glycemic control and significant weight reduction, especially in diverse populations. This study aimed to evaluate the efficacy and safety of the novel dual GLP-1/GIP receptor agonist Mazdutide in a Chinese adult population with **type 2 diabetes.

Patients treated with Mazdutide demonstrated significant improvements in both glycemic control and body weight compared to placebo. The 6 mg dose group achieved a mean HbA1c reduction of 2.1% from a baseline of 8.3%, significantly greater than the 0.3% reduction observed in the placebo group (p<0.001). Additionally, the 6 mg Mazdutide group experienced a mean body weight reduction of 10.5 kg, representing an 11.2% decrease from baseline, compared to a 1.5 kg (1.6%) reduction in the placebo group (p<0.001). The 3 mg dose also showed significant, albeit lesser, improvements. The most common adverse events were mild to moderate gastrointestinal issues (nausea, diarrhea), reported in 78% of the Mazdutide group versus 35% in the placebo group, with discontinuation rates due to adverse events at 8% vs 2% respectively. > The 6 mg dose of Mazdutide led to a remarkable 2.1% reduction in HbA1c and an 11.2% body weight loss, demonstrating superior efficacy over placebo in Chinese adults with type 2 diabetes.